[Clinical comparison of incidence of side effects of cilostazol analogs in treatment of diabetic foot syndrome].

The purpose of our study was to test the assumptions about possible side effects of two brand names of cilostazol. It included a total of 165 patients presenting with neuroischemic form of diabetic foot syndrome, stage IIA-IIB lower-limb chronic ischemia, moderate-to-severe distal sensorimotor neuropathy, as well as tissue damage according to the W (W1-W3) scale, with no urgent indications for limb amputation. The patients were willing to comply with the requirements for examination and treatment performed according to the algorithm at the 'Diabetic Foot' Center of Kazan after obtaining written informed consent. Two trade names of cilostazol analogs, i. e., 'Aducyl' and 'Pletax', were compared. The patients were divided into 2 groups, representative by the baseline data, in accordance with the received analog. The frequency of side effects, as well as the frequency of favorable and unfavorable outcomes were compared. The side effects encountered in both groups were as follows: headache, edematous syndrome in the lower extremities, destabilization of blood pressure, dermatitis in the lower extremities, tachycardia, shortness of breath, nausea, and general malaise. Also, the frequency of complications and the frequency of refusal to take the drug were compared. When analyzing the data obtained, it was found that the group of patients receiving Aducyl® included in the complex therapy regimen had significantly more favorable outcomes. Taking Pletax® was associated with a higher level of clinically verified complications. The chance of an unfavorable outcome during treatment with Pletax® was 2.43 times higher than that with Aducyl®.